Vanguri et al. [25] demonstrated the enhanced predictive capacity of integrating CT imaging and genomic features to forecast immunotherapy response in advanced non-small-cell lung cancer, achieving superior performance compared to individual biomarkers like tumor mutational burden and PD-L1 expression. The gene discussed is CD274; the disease is non-small cell lung carcinoma.